Associate Professor Michael Low

Learn more about Monash Health’s Haematology team.

Associate Professor Michael Low

Michael Low is a haematologist at Monash Health and Monash University. Michael works as a physician and pathologist. Michael additionally works in medical education. Michael currently holds the role of Director of Physician Education (DPE) at Casey Hospital, Director of the Greater South-Eastern BPT Consortium and chair of the Victorian/Tasmanian Director of Physician Training Group. Additionally Michael serves as the Director of Haematology Training at Monash Health.

Michael has served as the Myeloma lead at Monash Health since 2017 working closely with groups such as Myeloma Australia to provide education and support for patients. In addition, Michael is the principal investigator in over 20 completed, ongoing, and upcoming clinical trials mainly in myeloma therapy and also serves on the Australian Leukaemia and Lymphoma Group (ALLG) Myeloma working party.

Major Current Projects:

1. KILAMANJARO Trial: A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
2. EXCALIBUR Trial: A Phase 3 Randomised, open-label study of Iberdomide, Daratumumab and dexamethason versus Bortezomib, Daratumumab and Dexamethasone in participants with relapsed multiple myeloma.
3. SEALAND Trial: An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma.

Major Publications:

1. Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10.):e801-e812. doi: 10.1016/S2352-3026(23)00243-0.
2. Fedele PL, Liao Y, Gong J, Yao Y, van Deflt MF, Low MSY, Tai L, Herold MJ, Jackson JT, Teh C, Tan T, Gray DH, Tellier J, Grigoriadis G, Huang DCS, Shi W, Nutt SL, Willis SN. The transcription factor IRF4 represses pro-apoptotic BMF and BIM to licence Multiple Myeloma survival. Leukemia 2021, 35(7), pp. 2114–2118. doi: 10.1038/s41375-020-01078-0.
3. Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ, Fedele PF, Low MSY, Grigoriadis G, Harrison SJ, Strasser A, Roberts AW, Huang DCS, Nolan, GP, Gray DHD, Ko ME. Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death and Differentiation. Jul;27(7):2217-2233.; doi: 10.1038/s41418-020-0498-z. Epub 2020 Jan 27.
4. Low MSY, Brodie EJ, Fedele PL, Liao, Y, Grigoriadis G, Strasser A, Kallies A, Willis SN, Tellier J, Shi W, Gabrial S, O’Donnell K, Pitt C, Nutt SL, Tarlinton DM. IRF4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis. Cell Rep. 2019 Nov 26;29(9):2634-2645.e5. doi: 10.1016/j.celrep.2019.10.097
5. Low MS, Speedy J, Styles CE, De-Regil L, Pasricha S. Daily iron supplementation for improving anaemia, iron status and health in menstruating women. Cochrane Database of Systematic Reviews. 2016, Apr 18; Issue 4. Art. No.:CD009747. doi: 10.1002/14651858.CD009747.pub2